𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Anti–tumor necrosis factor α therapy and the risk of lymphoma in rheumatoid arthritis: No clear answer

✍ Scribed by Deborah P. M. Symmons; Alan J. Silman

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
50 KB
Volume
50
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

✦ Synopsis

The authors are the principal investigators of the British Society of Rheumatology (BSR) Biologics Register. The BSR receives financial support for the Register from the manufacturers of biologic agents currently licensed for use in the treatment of patients with inflammatory rheumatic diseases. The opinions expressed in this article are the authors' own and do not reflect the views of either the BSR or the sponsoring companies.

📜 SIMILAR VOLUMES

Anti–tumor necrosis factor α therapy and
Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis
✍ Sebastian Schneeweiss; Soko Setoguchi; Michael E. Weinblatt; Jeffrey N. Katz; Je 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB 👁 1 views

## Abstract ## Objective To assess the association between the initiation of anti–tumor necrosis factor α (anti‐TNFα) therapy and the risk of serious bacterial infections in routine care. ## Methods This was a cohort study of patients with rheumatoid arthritis (RA) in whom specific disease‐modif

Lymphoma in rheumatoid arthritis: The ef
Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti–tumor necrosis factor therapy in 18,572 patients
✍ Frederick Wolfe; Kaleb Michaud 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 2 views

## Abstract ## Objective The risk of lymphoma is increased in patients with rheumatoid arthritis (RA), and spontaneous reporting suggests that methotrexate (MTX) and anti–tumor necrosis factor (anti‐TNF) therapy might be associated independently with an increased risk of lymphoma. However, data fr